**THE BREAST CANCER INDEX™ (BCI) TEST REPORT**

**Result Summary**

BCI reports two independent genomic signatures. Four combinations of BCI risk category and Likelihood of Benefit from extended endocrine therapy are possible.

**Prognostic Result (5-10 y)**

Individualized risk of late recurrence is presented as a percentage in the Summary section, and is plotted on a continuous risk curve.

Patient result is also categorized as LOW or HIGH risk by BCI.

**Physician Information**

- **Treating Physician:**
  - First Last, M.D.
  - Facility Name
  - Facility Address
  - City, State Zip
  - Phone: (XXX) XXX-XXXX
  - Fax: (XXX) XXX-XXXX

- **Pathologist:**
  - First Last, M.D.
  - Laboratory Name
  - Laboratory Address
  - City, State Zip
  - Phone: (XXX) XXX-XXXX
  - Fax: (XXX) XXX-XXXX

**Patient & Order Information**

- **Order ID:** BDX15-00123
- **Patient Name:** First Last
- **DOB (Gender):** X/X/YYYY (F) XX Yrs Old
- **Sample ID:**
- **Date of Collection:**
- **Date Received:**
- **Date Reported:**

**Biology Information**

**LOW Risk of Late Recurrence (3.9% between years 5-10)**

**LOW RISK CATEGORY**

- **3.9% RISK** (95% CI: 1.6% - 6.2%)
- **OF DISTANT RECURRENCE FOR ER+, LYMPH NODE-NEGATIVE PATIENTS AFTER YEAR 5**

**HIGH LIKELIHOOD OF BENEFIT FROM EXTENDED ENDOCRINE THERAPY**

**HIGH Likelihood of Benefit**

**TREATMENT BENEFIT BASED ON INDEPENDENT VALIDATION DATA OF BCI PREDICTIVE IN MA.17**

Patients with a High BCI Predictive result had **67% relative risk reduction** (p=0.007) when treated with extended endocrine therapy in the MA.17 validation study.

**Additional Comments:**

- **Laboratory Director:**
  - CLIA #: 05-D1065727 CLF334843
  - Electronically Signed By:

- **Biotheranostics, Inc.**
  - 9640 Towne Center Drive, Suite 200 • San Diego, CA 92121 Tel: 877.886.6739

**Clinically Actionable Information**

- Consider continuation of endocrine therapy based on patient tolerability and comorbidities
The Breast Cancer Index (BCI) Risk of Distant Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 years) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients); and 2) prediction of likelihood of benefit from extended (>5 years) endocrine therapy. Risk of recurrence applies only to LN- patients. Positive LN status increases risk, and LN+ patients should be considered at high risk of recurrence.7

For additional information including test description, methodology, clinical report and interpretation, please see: www.breastcancerindex.com/ordering

Further Information

Validation - Risk of overall recurrence: BCI separates patients into three distinct categories for patients in which BCI is ordered to assess overall risk of recurrence (0-10 years).

Validation - Risk of late recurrence: In clinical studies, BCI Intermediate risk had a statistically similar risk of late recurrence as the BCI High risk group; thus, risk categories are reported as Low or High risk only.